Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at Wall Street Zen

Wall Street Zen downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.

Other analysts have also issued reports about the company. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Up 1.7%

NASDAQ:SUPN opened at $46.98 on Friday. The stock has a market capitalization of $2.73 billion, a PE ratio of -92.12, a price-to-earnings-growth ratio of 0.99 and a beta of 0.54. The firm’s 50 day moving average is $46.46 and its 200 day moving average is $49.23. Supernus Pharmaceuticals has a 12 month low of $32.83 and a 12 month high of $59.68.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SUPN. Tudor Investment Corp ET AL purchased a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $1,434,000. Phocas Financial Corp. bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $4,042,000. Westover Capital Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $1,587,000. Elmind Capital LP purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $994,000. Finally, Aberdeen Group plc bought a new position in Supernus Pharmaceuticals in the 4th quarter worth about $13,497,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.